Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
You may also be interested in...
Lamberto Andreotti, currently president, was the front-runner in a year-long, three-way race to replace Cornelius.
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster